Abstract
Multiple myeloma treatment often involves combination therapies which may lead to thrombotic consequences. Is there an effective way to ameliorate these risks to maximise treatment outcomes?
Author supplied keywords
- Aspirin (PubChem CID: 2244)
- Bortezomib (PubChem CID: 387447)
- Carfilzomib (PubChem CID: 11556711)
- Cyclophosphamide (PubChem CID: 2907)
- Daratumumab/Anti-CD38 (PubChem SID: 378174561)
- Dexamethasone (PubChem CID: 5743)
- Histone deacetylase (HDAC) inhibitors (PubChem CID: 10095659)
- Ixazomib (PubChem CID: 772)
- Lenalidomide (PubChem CID: 216326)
- Low molecular weight heparin (PubChem CID: 772)
- Panobinostat (PubChem CID: 6918837)
- Pomalidomide (PubChem CID: 134780)
- Thalidomide (PubChem CID: 5426)
Cite
CITATION STYLE
APA
Alanazi, F., Kwa, F. A. A., Burchall, G., & Jackson, D. E. (2020, February 1). New generation drugs for treatment of multiple myeloma. Drug Discovery Today. Elsevier Ltd. https://doi.org/10.1016/j.drudis.2019.11.008
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free